房颤患者中慢性阻塞性肺疾病的患病率、管理及影响:一项纳入420万患者的系统综述与荟萃分析
该系统综述与荟萃分析纳入46项研究,估计房颤患者中COPD的合并患病率为13%(95%CI 10-16%)。COPD与更多合并症、更高CHA2DS2-VASc评分及较低β受体阻滞剂处方率相关,并增加全因死亡、心血管死亡和大出血风险;在房颤合并COPD患者中,β受体阻滞剂使用未显著改变结局。
要点
- 房颤患者中COPD合并患病率为13%,提示需常规筛查。
- COPD增加房颤患者全因死亡、心血管死亡及大出血风险。
- 房颤合并COPD患者使用β受体阻滞剂未增加不良结局风险。
核心结论
- COPD在房颤患者中常见,患病率13%,与合并症负担增加、管理差异及更差结局相关。
- β受体阻滞剂治疗不增加房颤合并COPD患者的不良结局风险。
研究设计与样本
- 系统综述与荟萃分析,纳入46项报告房颤患者COPD患病率的研究。
主要发现
- COPD合并患病率为13%(95%CI 10-16%),95%预测区间2-47%。
- COPD与更高合并症患病率、更高CHA2DS2-VASc评分相关。
- COPD患者β受体阻滞剂处方率更低(OR 0.77,95%CI 0.61-0.98)。
- COPD与更高全因死亡(OR 2.22,95%CI 1.93-2.55)、心血管死亡(OR 1.84,95%CI 1.39-2.43)及大出血(OR 1.45,95%CI 1.17-1.80)风险相关。
- 在房颤合并COPD患者中,根据β受体阻滞剂使用情况未观察到结局显著差异。
临床怎么用
- 对房颤患者应考虑筛查COPD,以识别高风险人群。
- 房颤合并COPD患者使用β受体阻滞剂时,无需因担心不良结局而避免。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Prevalence of chronic obstructive pulmonary disease (COPD) in atrial fibrillation (AF) patients is unclear, and its association with adverse outcomes is often overlooked. Our aim was to estimate the prevalence of COPD, its impact on clinical management and outcomes in patients with AF, and the impact of beta-blockers (BBs) on outcomes in patients with COPD. METHODS AND RESULTS: A systematic review and meta-analysis was conducted according to international guidelines. All studies reporting the prevalence of COPD in AF patients were included. Data on comorbidities, BBs and oral anticoagulant prescription, and outcomes (all-cause death, cardiovascular (CV) death, ischaemic stroke, major bleeding) were compared according to COPD and BB status. Among 46 studies, pooled prevalence of COPD was 13% [95% confidence intervals (CI) 10-16%, 95% prediction interval 2-47%]. COPD was associated with higher prevalence of comorbidities, higher CHA2DS2-VASc score and lower BB prescription [odds ratio (OR) 0.77, 95% CI 0.61-0.98]. COPD was associated with higher risk of all-cause death (OR 2.22, 95% CI 1.93-2.55), CV death (OR 1.84, 95% CI 1.39-2.43), and major bleeding (OR 1.45, 95% CI 1.17-1.80); no significant differences in outcomes were observed according to BB use in AF patients with COPD. CONCLUSION: COPD is common in AF, being found in 13% of patients, and is associated with increased burden of comorbidities, differential management, and worse outcomes, with more than a two-fold higher risk of all-cause death and increased risk of CV death and major bleeding. Therapy with BBs does not increase the risk of adverse outcomes in patients with AF and COPD.
引用
- Romiti GF, Corica B, Pipitone E, et al. Prevalence, management and impact of chronic obstructive pulmonary disease in atrial fibrillation: a systematic review and meta-analysis of 4,200,000 patients. Eur Heart J. 2021. PMID: 34333599. doi:10.1093/eurheartj/ehab453
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。